$WAT

Goldman Sachs Adjusts Price Target on Waters to $515 From $465, Maintains Buy Rating

Goldman Sachs raised its price target for Waters Corporation to $515 from $465, maintaining a Buy rating. The stock closed at $421.63, down 1.88% over 5 days but up 11% year-to-date. The adjustment is based on a weighted average of valuation, EPS revisions, and visibility metrics.

Original reporting
Published Sep 21, 2026, 9:44 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 10:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$WAT
Bullish
medium confidence
Mentioned
$WAT
Relevance
6/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$WATBullishMed
01

Why it matters

The upgrade signals a more optimistic view of Waters' earnings trajectory and may attract buy-side interest.

02

Market read

A modest analyst upgrade that could nudge the stock toward its new target, with limited broader market impact.

03

What to watch

Potential headwinds from regulatory changes or supply chain constraints are not addressed in the upgrade.

Relevance 6/10Novelty 6/10Timing: today

Background

Goldman Sachs periodically updates price targets based on its valuation models and market outlook.

Company-level read

Ticker impact

$WATBullishMedium confidence
Context

Goldman Sachs raised Waters' price target to $515 from $465, maintaining a Buy rating.

Expected impact

Potential modest price appreciation toward the new target level.

Evidence & confidence

Price target lift reflects improved valuation outlook; however, the move is modest and not tied to a material corporate event.

Market effects

May lift sentiment for the broader water treatment sector as analysts view the space more favorably.

Limited to U.S. markets where Waters trades; negligible regional effect.

Minor, confined to investors tracking industrial and specialty chemicals.

Counterpoint

The target raise could be premature if underlying earnings growth does not meet expectations.

Key entities

  • Goldman Sachs

    Equity research firm providing the price target revision.

  • Waters Corporation

    U.S.-listed provider of analytical instruments and software.

Related articles

$BRKRHighAI 8/10

Research Tools & Consumables Stocks Q2 Highlights: Bruker (NASDAQ:BRKR)

Bruker (BRKR) reported Q2 revenue of $838.5M, up 5.2% YoY but missing estimates by 1.9%. Its stock fell 7.3% post-results. Avantor (AVTR) beat expectations with $1.69B revenue, up flat YoY, and its stock rose 17.1%. Waters (WAT) saw 113% revenue growth but mixed guidance, with its stock up 10.3%. Bio-Techne (TECH) and Danaher (DHR) also reported earnings, with TECH flat and DHR up 5.7% post-results.

$WATHighAI 8/10

Is Wall Street Bullish or Bearish on Waters Corporation Stock?

Waters Corporation (WAT), a $40.7B life sciences and diagnostics company, reported Q2 2026 adjusted EPS of $3.05 and revenue of $1.65B, exceeding expectations. The stock has risen 43% over 52 weeks, outperforming the S&P 500. Analysts expect 10.9% EPS growth for 2026, with a consensus 'Moderate Buy' rating and a mean price target of $438.43.

$WATMed

WAT Upgraded by Piper Sandler -- Price Target Raised to $480

Piper Sandler upgraded Waters Corporation (WAT) to Overweight, raising its price target to $480 from $400. The company's stock is currently trading at $423.22, slightly above its GF Value™ of $411.65, indicating a 2.8% overvaluation. Waters Corporation has a GF Score™ of 95/100, reflecting strong growth and momentum but moderate financial strength. Insider activity shows recent selling of $1,442,930 worth of shares.

$WATHighAI 9/10

Waters (WAT) Q2 2026 Earnings Call Transcript

Waters (WAT) reported Q2 2026 revenue of $1.645 billion, above the top of guidance, with 9% organic growth and adjusted EPS of $3.05. Full-year 2026 guidance was raised to 7% to 9% organic revenue growth and adjusted EPS of $14.45 to $14.65. Management cited cost actions, FX headwinds, China DRG headwinds, and progress in acquired biosciences and diagnostics.

$WATMedAI 8/10

Waters Q2 Earnings Call Highlights

Waters (NYSE:WAT) reported Q2 updates from its earnings call. Materials Science Division revenue rose to $87M. Biosciences and Diagnostic Solutions acquired from BD generated $817M revenue. Waters raised FY organic constant-currency growth outlook to 7% to 9%, projecting FY reported revenue of $3.370B to $3.431B and adjusted EPS of $14.45 to $14.65.